These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 7759228)

  • 1. Ethnic distribution of the fragile X syndrome in Israel: evidence of founder chromosomes(?).
    Dar H; Chemke T; Schaap T; Chaki R; Bait-Or H; Cohen H; Borochowitz Z; Falik-Borenstein Z; Gelman-Kohan Z; Chemke J
    Isr J Med Sci; 1995 May; 31(5):323-5. PubMed ID: 7759228
    [No Abstract]   [Full Text] [Related]  

  • 2. Fragile X founder effects and new mutations in Finland.
    Zhong N; Kajanoja E; Smits B; Pietrofesa J; Curley D; Wang D; Ju W; Nolin S; Dobkin C; Ryynänen M; Brown WT
    Am J Med Genet; 1996 Jul; 64(1):226-33. PubMed ID: 8826481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragile X founder chromosomes in Italy: a few initial events and possible explanation for their heterogeneity.
    Chiurazzi P; Genuardi M; Kozak L; Giovannucci-Uzielli ML; Bussani C; Dagna-Bricarelli F; Grasso M; Perroni L; Sebastio G; Sperandeo MP; Oostra BA; Neri G
    Am J Med Genet; 1996 Jul; 64(1):209-15. PubMed ID: 8826478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragile X founder chromosome effects: linkage disequilibrium or microsatellite heterogeneity?
    Zhong N; Ye L; Dobkin C; Brown WT
    Am J Med Genet; 1994 Jul; 51(4):405-11. PubMed ID: 7943008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for high-risk haplotypes and (CGG)n expansion in fragile X syndrome in the Hellenic population of Greece and Cyprus.
    Syrrou M; Patsalis PC; Georgiou I; Hadjimarcou MI; Constantinou-Deltas CD; Pagoulatos G
    Am J Med Genet; 1996 Jul; 64(1):234-8. PubMed ID: 8826482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylsulfatase A pseudodeficiency: a common polymorphism which is associated with a unique haplotype.
    Zlotogora J; Furman-Shaharabani Y; Goldenfum S; Winchester B; von Figura K; Gieselmann V
    Am J Med Genet; 1994 Aug; 52(2):146-50. PubMed ID: 7801999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No founder effect detected in Jewish Ashkenazi patients with fragile-X syndrome.
    Pesso R; Barkai G; Ravia Y; Gak E; Frydman M; Goldman B; Friedman E
    Hum Genet; 1997 Dec; 101(2):186-9. PubMed ID: 9402966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A complex mutable polymorphism located within the fragile X gene.
    Zhong N; Dobkin C; Brown WT
    Nat Genet; 1993 Nov; 5(3):248-53. PubMed ID: 8275089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haplotypic determinants of instability in the FRAX region: Concatenated mutation or founder effect?
    Ennis S; Murray A; Morton NE
    Hum Mutat; 2001; 18(1):61-9. PubMed ID: 11438994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragile X founder effects in Argentina.
    Bonaventure G; Torrado M; Barreiro C; Chertkoff L
    Am J Med Genet; 1998 Sep; 79(3):200-4. PubMed ID: 9788562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathology of the fragile X syndrome.
    Tsongalis GJ; Silverman LM
    Arch Pathol Lab Med; 1993 Nov; 117(11):1121-5. PubMed ID: 8239933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of fragile X syndrome in a sample from Spanish Basque country.
    Arrieta I; Criado B; Martinez B; Telez M; Nuñez T; Peñagarikano O; Ortega B; Lostao CM
    Ann Genet; 1999; 42(4):197-201. PubMed ID: 10674158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragile X syndrome and 22q11.2 microdeletion in the same sibship.
    Missirian C; Moncla A; Voelckel MA; Ravix V; Philip N
    Am J Med Genet; 2000 Dec; 95(4):358-60. PubMed ID: 11186890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion in the FMR1 gene in a fragile-X male.
    Mannermaa A; Pulkkinen L; Kajanoja E; Ryynänen M; Saarikoski S
    Am J Med Genet; 1996 Aug; 64(2):293-5. PubMed ID: 8844068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong founder effect for the fragile X syndrome in Sweden.
    Malmgren H; Gustavson KH; Oudet C; Holmgren G; Pettersson U; Dahl N
    Eur J Hum Genet; 1994; 2(2):103-9. PubMed ID: 8044655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [DNA diagnosis of fragile X syndrome in a family. A new type of heredity--dynamic mutations].
    Eiken HG; Boman H; Apold J
    Tidsskr Nor Laegeforen; 1993 Oct; 113(26):3236-9. PubMed ID: 8236216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended gene diversity at the FMR1 locus and neighbouring CA repeats in a sub-Saharan population.
    Chiurazzi P; Destro-Bisol G; Genuardi M; Oostra BA; Spedini G; Neri G
    Am J Med Genet; 1996 Jul; 64(1):216-9. PubMed ID: 8826479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ellis-van Creveld syndrome and the Amish.
    McKusick VA
    Nat Genet; 2000 Mar; 24(3):203-4. PubMed ID: 10700162
    [No Abstract]   [Full Text] [Related]  

  • 19. A point mutation in the FMR-1 gene associated with fragile X mental retardation.
    De Boulle K; Verkerk AJ; Reyniers E; Vits L; Hendrickx J; Van Roy B; Van den Bos F; de Graaff E; Oostra BA; Willems PJ
    Nat Genet; 1993 Jan; 3(1):31-5. PubMed ID: 8490650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experimental therapy: reactivation of the FMR1 gene involved in fragile X syndrome].
    Chiurazzi P; Neri G
    Rev Neurol; 2001 Oct; 33 Suppl 1():S62-5. PubMed ID: 12447822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.